KPJ Healthcare Launches First Orthopaedic and Rheumatology Centre of Excellence Under the KPJ Health System

BUKIT MERTAJAM, Malaysia, Aug. 4, 2026 /PRNewswire/ -- KPJ Healthcare Berhad ("KPJ Healthcare" or "the Group") today launched its first Orthopaedic and Rheumatology Centre of Excellence ("CoE") at KPJ Penang Specialist Hospital ("KPJ Penang"), marking the third CoE under the KPJ Health System ("KPJHS"). As Malaysia's first private integrated academic health system, the Group continues to advance specialised musculoskeletal and joint care through the integration of Practice, Education, Research and Innovation.

Designed to support the management of complex conditions, the Orthopaedic and Rheumatology CoE integrates orthopaedic subspecialties, rheumatology and multidisciplinary expertise such as rehabilitation within a coordinated model of care. Bringing together consultations, diagnostic imaging, treatment rooms and advanced rehabilitation together on a single floor, the Centre provides a more seamless patient experience from diagnosis through rehabilitation and recovery. Comprehensive services include general orthopaedics, spine surgery, arthroplasty (joint replacement), arthroscopy and sports surgery, foot and ankle surgery, hand and microsurgery, paediatric orthopaedics, trauma and fracture management, rheumatology and pain services.

Its capabilities are further enhanced by AI-assisted robotic joint replacement surgery, computer-assisted navigation and minimally invasive surgical techniques, supporting greater surgical precision, improved mobility and faster functional recovery. Supporting these capabilities are tailored rehabilitation programmes, including post-spine surgery, post-sports injury and paediatric orthopaedic rehabilitation, supported by specialised technologies such as an anti-gravity treadmill.

YBhg. Datuk Syed Mohamed Syed Ibrahim, Chairman of the KPJHS Governing Council, Chairman of KPJ Healthcare University Sdn. Bhd. and President & Chief Executive of Johor Corporation ("JCorp") said, "Our ambition for every Centre of Excellence in the KPJ Health System, including the one we launch today, is not that it should remain a Centre in perpetuity. Our ambition is for it to continue growing, strengthening its clinical, academic and research capabilities until, over time, it is elevated into an Institute: a destination in its clinical discipline, a generator of published evidence, a trainer of national and international leaders, and a partner sought after by industry, academia and governments. World-class in the fullest meaning of that phrase."

The Orthopaedic and Rheumatology CoE builds on the establishment of the Heart & Lung Centre of Excellence at Johor Specialist Hospital and the Neuroscience & Stroke Centre of Excellence at Damansara Specialist Hospital 2, reinforcing KPJ Healthcare's long-term strategy to establish 15 Centres of Excellence nationwide by 2030 under the KPJHS. Through its integrated hub model anchored by KPJ Penang Specialist Hospital together with KPJ Selangor Specialist Hospital, the Centre enables shared expertise, common clinical standards, coordinated research and multidisciplinary collaboration across the KPJ Health System, demonstrating how specialised care can be delivered through one integrated academic health system. This integrated approach also provides the platform to accelerate the convergence of artificial intelligence, genomics and value-based care in shaping the future of specialised healthcare delivery.

KPJ Penang is a 270-bed tertiary hospital supported by more than 50 resident consultants across over 20 medical specialties. The establishment of the Orthopaedic and Rheumatology CoE further strengthens the hospital's role within the KPJHS. Through the Centre, patients benefit from greater access to advanced orthopaedic treatments that have demonstrated improved patient-reported outcomes and shorter hospital stays. Complementing these capabilities, KPJ Penang is also the first in the Northern Region to provide advanced wound care management and, in collaboration with KPJ Healthcare University, is developing Malaysia's first AI-assisted remote telewound care programme.

About KPJ Healthcare Berhad 

KPJ Healthcare operates 30 hospitals across Malaysia and four Ambulatory Care Centres, serving 3.3 million patients annually with 1,491 medical consultants. Nineteen hospitals are accredited by MSQH and four by JCI. As Malaysia's first private healthcare provider to establish an Academic Health System, KPJHS integrates practice, education and research & innovation to drive clinical excellence and patient experience. Beyond hospitals, KPJ Healthcare operates Klinik Waqaf An-Nur (KWAN) clinics, dialysis centres and mobile clinics nationwide, and offers more than 40 academic programmes at KPJ Healthcare University (KPJU). KPJ Healthcare has been a constituent of the Bursa Malaysia FTSE4Good Index since 2016.

 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

KPJ Healthcare Launches First Orthopaedic and Rheumatology Centre of Excellence Under the KPJ Health System

The same genomic technology once limited to specialist programs is now accessible to anyone, paired with an AI platform built on over a decade of clinical data and a new multimillion-dollar collaboration with Insilico Medicine to predict disease before it begins.

SAN FRANCISCO, Aug. 4, 2026 /PRNewswire/ -- Human Longevity, Inc. (HLI), a precision health and longevity technology company, today announced the availability of Genomics for All, a clinical-grade whole genome sequencing product priced at $599. The offering sequences all 6.4 billion base pairs of an individual's DNA and delivers AI-interpreted results through the HLI app, with no clinic visit required.

Unlike consumer ancestry tests, which analyse less than 0.02% of the genome using SNP chip technology, Genomics for All sequences the entire genome at 30x clinical-grade depth, the coverage standard required for medically meaningful interpretation. The result is a fundamentally different class of information: one capable of identifying inherited disease risk across more than 10,000 genetic variants, flagging pharmacogenomic markers that affect how individuals respond to common medications including statins and GLP-1 receptor agonists, and screening for carrier status in hereditary conditions. The report also covers health-related traits across nutrition, metabolism, and exercise response.

A central feature of the product is its AI-powered re-analysis capability. Because the genome itself does not change, HLI re-analyses each client's genomic data on an ongoing basis as new research is published, new disease-gene associations are identified, and clinical guidelines are updated. When a new clinically relevant finding emerges, HLI proactively alerts affected clients, often within 24 hours of publication. This transforms a one-time sequencing event into a continuously evolving health resource.

"Our founder Dr. Venter helped make it possible for humanity to read the human genome," said Wei-Wu He, Ph.D., Chairman and CEO of Human Longevity. "With Genomics for All, we are continuing that vision by helping more people understand what their genome may mean for their long-term health. Our goal is not to replace physicians or make deterministic predictions, but to provide better information that can support more informed conversations, earlier awareness, and more personalised care."

Genomics for All sits within a broader AI-driven platform that HLI has been building for over a decade. In May 2026, HLI announced the launch of Human Life Foundation Models, Inc. (HLFM), a dedicated AI entity developed in partnership with Insilico Medicine, a clinical-stage generative AI biotechnology company. The multimillion-dollar collaboration aims to develop what the companies describe as the industry's first large-scale AI foundation model dedicated to longevity science, drawing on HLI's multimodal clinical and genomic datasets collected across more than 10,000 clients to identify the biological mechanisms of aging and enable predictive healthcare.

Genomics for All is the entry-level offering in HLI's broader suite of precision health programs, which also includes more comprehensive assessments combining advanced imaging, biomarker panels, and clinician-guided care. The scientific advisory board includes Nobel laureates Dr. Geoffrey Hinton and Dr. Michael Levitt.

Genomics for All is available now at humanlongevity.com/genomics for $599.

About Human Longevity, Inc.
Human Longevity, Inc. is a precision health company focused on helping individuals better understand and manage long-term health through genomics, AI-supported interpretation, advanced diagnostics, and clinician-guided care. Founded in 2013 by Dr. J. Craig Venter and other life sciences leaders, the company has invested approximately $600M in research and worked with more than 10,000 clients across its clinics in San Diego and San Francisco. HLI's programs include Genomics for All, Executive Health, 100+ Care, and 100+ Concierge. For more information, visit www.humanlongevity.com.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Human Longevity Makes Clinical-Grade Whole Genome Sequencing Available to All for $599